Johannes Limbrock

Learn More
Orofacial regulation therapy for children with Down’s syndrome was introduced to Europe in Munich in 1978. Since then, many clinical studies have provided scientific evidence that this therapeutic approach enhances the orofacial function and facial appearance of children with trisomy 21. Only few long-term results have been published to date. In the present(More)
Das Sjögren-Larsson-Syndrom ist ein seltenes, ubiquitär auftretendes neurokutanes Erscheinungsbild mit autosomal-rezessivem Erbmodus. Die Klinik ist durch die Trias kongenitale Ichthyose, spastische Di- oder Tetraplegie sowie mentale Retardierung gekennzeichnet. Ursächlich liegt dem Erscheinungsbild ein Mangel des Enzyms Fettaldehyddehydrogenase, einer(More)
The aim of this investigation was to evaluate the long-term orofacial development of Down children who received plate therapy according to Castillo Morales in their early childhood. The orofacial development of 27 Down children was documented before and after plate therapy and at a follow-up examination 13 years +/- 6 months after initiation of therapy. The(More)
The aim of stimulating plate therapy in patients with trisomy 21 is to correct orofacial dysfunctions and prevent the establishment of subsequent morphological characteristics such as protrusion of the incisors and pseudoprognathia. This study investigated the effectiveness of this type of therapy in improving skeletal traits of patients with Down syndrome.(More)
  • 1